Literature DB >> 32055273

Mouse tail models of secondary lymphedema: fibrosis gradually worsens and is irreversible.

Chenxiao Zhou1, Wanchun Su2, Haotian Han1, Na Li3, Gang Ma4, Lei Cui1,3.   

Abstract

Although the mouse tail model of secondary lymphedema has been widely used in research, our knowledge regarding some of the characteristic changes in this model is lacking. Therefore, in the current study, we aimed to identify pathologic changes after surgery. Tail lymphedema was created in C57BL/6J mice by disconnecting both superficial and deep lymphatic vessels. The surgery resulted in chronic edema formation with the proliferation of subcutaneous adipose tissue, deposition of fibrotic tissue, and gradual increase in CD4+ T lymphocyte infiltration. Furthermore, dramatic expansion and an increased number of lymphatic vessels were observed postoperatively. Lymphatic reflux was established at least 8 weeks after surgery, as evidenced by staining of the scar from the surgical excision. In addition, tissue fibrosis was irreversible, although CD4+ T cell infiltration, tail swelling, and subcutaneous adipose hyperplasia were alleviated over time. We also show that necrosis could be effectively avoided by paying attention to several details in the modeling process. As animal models play a key role in exploring the pathophysiology of disease, our findings provide strong support for the study of lymphedema. The irreversibility of fibrosis suggests the importance of treating lymphedema by preventing fibrosis development. IJCEP
Copyright © 2020.

Entities:  

Keywords:  Mouse models; fibrosis; lymphedema

Year:  2020        PMID: 32055273      PMCID: PMC7013376     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  50 in total

1.  Therapeutic lymphangiogenesis using stem cell and VEGF-C hydrogel.

Authors:  Ji Hye Hwang; In Gul Kim; Ji Young Lee; Shuyu Piao; David S Lee; Tae Seung Lee; Jeong Chan Ra; Ji Youl Lee
Journal:  Biomaterials       Date:  2011-03-21       Impact factor: 12.479

2.  A novel serum protein similar to C1q, produced exclusively in adipocytes.

Authors:  P E Scherer; S Williams; M Fogliano; G Baldini; H F Lodish
Journal:  J Biol Chem       Date:  1995-11-10       Impact factor: 5.157

Review 3.  Entanglement of GSK-3β, β-catenin and TGF-β1 signaling network to regulate myocardial fibrosis.

Authors:  Yuanjun Guo; Manisha Gupte; Prachi Umbarkar; Anand Prakash Singh; Jennifer Y Sui; Thomas Force; Hind Lal
Journal:  J Mol Cell Cardiol       Date:  2017-07-27       Impact factor: 5.000

Review 4.  TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target?

Authors:  M Martin; J Lefaix; S Delanian
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-05-01       Impact factor: 7.038

5.  Diphtheria toxin-mediated ablation of lymphatic endothelial cells results in progressive lymphedema.

Authors:  Jason C Gardenier; Geoffrey E Hespe; Raghu P Kataru; Ira L Savetsky; Jeremy S Torrisi; Gabriela D García Nores; Joseph J Dayan; David Chang; Jamie Zampell; Inés Martínez-Corral; Sagrario Ortega; Babak J Mehrara
Journal:  JCI Insight       Date:  2016-09-22

6.  Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation.

Authors:  Naomi Hosogai; Atsunori Fukuhara; Kazuya Oshima; Yugo Miyata; Sachiyo Tanaka; Katsumori Segawa; Shigetada Furukawa; Yoshihiro Tochino; Ryutaro Komuro; Morihiro Matsuda; Iichiro Shimomura
Journal:  Diabetes       Date:  2007-04       Impact factor: 9.461

7.  Fibrosis is a key inhibitor of lymphatic regeneration.

Authors:  Tomer Avraham; Nicholas W Clavin; Sanjay V Daluvoy; John Fernandez; Marc A Soares; Andrew P Cordeiro; Babak J Mehrara
Journal:  Plast Reconstr Surg       Date:  2009-08       Impact factor: 4.730

8.  Adipose-derived stem cell transplantation for therapeutic lymphangiogenesis in a mouse secondary lymphedema model.

Authors:  Shuhei Yoshida; Rodrigo Hamuy; Yuuichi Hamada; Hiroshi Yoshimoto; Akiyoshi Hirano; Sadanori Akita
Journal:  Regen Med       Date:  2015       Impact factor: 3.806

9.  AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation.

Authors:  Rangnath Mishra; Barbara L Cool; Keith R Laderoute; Marc Foretz; Benoit Viollet; Michael S Simonson
Journal:  J Biol Chem       Date:  2008-02-04       Impact factor: 5.157

10.  Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis.

Authors:  Li-Juan Zhang; Wei-Da Zheng; Yun-Xin Chen; Yue-Hong Huang; Zhi-Xin Chen; Sheng-Jun Zhang; Mei-Na Shi; Xiao-Zhong Wang
Journal:  Hepatogastroenterology       Date:  2007 Oct-Nov
View more
  3 in total

Review 1.  Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis.

Authors:  Hector Lafuente; Ibon Jaunarena; Eukene Ansuategui; Arantza Lekuona; Ander Izeta
Journal:  Stem Cell Res Ther       Date:  2021-11-20       Impact factor: 6.832

Review 2.  Lymphatic Vessel Regression and Its Therapeutic Applications: Learning From Principles of Blood Vessel Regression.

Authors:  Faisal Masood; Rohan Bhattaram; Mark I Rosenblatt; Andrius Kazlauskas; Jin-Hong Chang; Dimitri T Azar
Journal:  Front Physiol       Date:  2022-03-22       Impact factor: 4.755

3.  Comprehensive analysis reveals potential hub genes and therapeutic drugs in an acquired lymphedema model.

Authors:  Chaoran Qiu; Jiemei Chen; Hui Huang; Zhiquan Lin; Yiwen Zhang; Chunbang Liao; Mei Yang; Yuting Qu; Shengchao Huang; Weiwen Li; Xiaoping Li
Journal:  Gland Surg       Date:  2022-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.